<DOC>
	<DOC>NCT00790946</DOC>
	<brief_summary>The purpose of this study is to consider the following points in patients with hypertension who complicated by metabolic syndrome for Valsartan basis treatment and an existing, standard treatment. - Blood pressure control - Changing of adiponectin and plasminogen activator inhibitor-1 - Influence metabolizing and cardiac function, etc.</brief_summary>
	<brief_title>Kagoshima Collaborate Trial in Metabolic Syndrome (KACT Study)</brief_title>
	<detailed_description>The primary endpoints are: - blood pressure control - Adiponectin and plasma type1 plasminogen active inhibitor The secondary endpoints are - HOMA-IR - HbA1c - TNF-α - IL-6 - Plasma B-type natriuretic peptide - LVMI - E/A ratio - Tei-index - Apo-J</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Out patients with hypertension male and female Systolic blood pressure (SBP)≧140mmHg and/or diastolic blood pressure (DBP)≧90 mmHg Waist Surrounding diameter male≧85cm female≧90cm Patient who is treating either high triglyceride,low HDL,or diabetes mellitus Patient who is untreatment high triglyceride blood syndrome and low HDL blood syndrome,diabetes mellitus is triglceride≧150mg/dl and/or HDL cholesterol &lt; 40 mg/dl or fasting blood glucose ≧110 mg/dl Untreated patients with hypertension,or patients is treated with antihypertensive agents except for ACEI and ARB Patient who is using ACEI and ARB Serum creatinine ≧ 3 mg/dl Liver impairment History of allergy to valsartan Pregnant women Judgment by the physician that participation was unwise on the basis of patient characteristics and drug safety</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>valsartan</keyword>
	<keyword>Metabolic syndrome</keyword>
</DOC>